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Background: The purpose of this study was to compare two biochemical markers, which have been previously
used to determine the degrees of alveolar bone destruction, in evaluating periodontal disease severity.
Methods: The WF6 epitope of chondroitin sulfate (CS) and the alkaline phosphatase (ALP) levels were determined
in gingival crevicular fluid (GCF) samples collected from patients with various degrees of disease severity, including
ten patients with gingivitis (50 gingivitis sites) and 33 patients with chronic periodontitis (including gingivitis, slight,
moderate, and severe periodontitis sites; n = 50 each), as well as from ten healthy volunteers (50 healthy sites) by
Periopaper strips. The levels of CS and ALP were measured by an ELISA and a fluorometric assay, respectively.
Results: The results demonstrated low levels of CS and ALP in non-destructive and slightly destructive periodontitis
sites, whereas significantly high levels of these two biomolecules were shown in moderately and severely destructive
sites (p < 0.05). Although a significant difference in CS levels was found between moderate and severe periodontitis
sites, no difference in ALP levels was found. Stronger correlations were found between CS levels and periodontal
parameters, including probing depth, loss of clinical attachment levels, gingival index and plaque index, than between
ALP levels and these parameters.
Conclusions: It is suggested that the CS level is a better diagnostic marker than the ALP level for evaluating distinct
severity of chronic periodontitis.
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At present, diagnosis of periodontal diseases and evalu-
ation of their severity are based on conventional clinical
parameters and radiographic findings. However, these
methods cannot rapidly detect early periodontal tissue
losses and are, therefore, insufficient to determine the
degrees of disease severity. Therefore, different types of
adjunctive tools are introduced into clinical practice and
provide more validity for correct diagnosis and proper
treatment planning [1]. Up to the present, several bio-
markers have been used for diagnosis and assessment of* Correspondence: suttichaikris@yahoo.com
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article, unless otherwise stated.periodontal disease status as well as prognostic prediction
of periodontal disease progression because of their sensi-
tivity and specificity. A number of previous studies have
recommended gingival crevicular fluid (GCF), a serum
exudate, as a source of biomolecules sampling in order to
evaluate periodontal disease status [2-4]. GCF cons-
tituents are composed of more than 65 components
that have been reported as possible biomarkers for
periodontal disease progression [5]. These include inflam-
matory mediators and host-response modifiers [6-8],
host-derived enzymes and their inhibitors [9-11] and tis-
sue breakdown products [12-14].
Among host-derived enzymes, positive association
between alkaline phosphatase (ALP) and periodontal
disease activity has previously been reported [15,16].
This membrane-bound glycoprotein, which functionsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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phosphate-binding protein [17]. ALP is released from
neutrophils and, thus, detected in GCF collected from
inflamed periodontium as well as from osteoblasts dur-
ing bone formation [18,19]. With respect to tissue-
breakdown products, several studies have investigated
the levels of proteoglycans and their constituent gly-
cosaminoglycans (GAGs) in periodontal tissues and
GCF from patients with periodontal disease in com-
parison to those from healthy controls [20,21]. Major
GAGs present in periodontal tissues are dermatan sul-
fate, hyaluronan, chondroitin sulfate (CS) and keratan
sulfate. A main source of GAGs in GCF is derived from
extracellular matrix degradation of periodontal tissues
during the progression of periodontal disease. Conse-
quently, raised levels of GAGs detectable in GCF dir-
ectly reflect, and are associated with the destruction of
periodontal tissues, especially alveolar bone, at the dis-
eased site [22-25]. Furthermore, elevated levels of CS
in GCF are apparently associated with four clinical pa-
rameters of periodontal status, which serve as gold
standards for periodontal inflammation and destruc-
tion [14]. In addition to periodontal disease, CS levels
can be precisely detected in physiologic tooth move-
ment [26,27] and in patients with pathologic inflamma-
tory disorders, such as degenerative joint diseases
[28,29].
Although a number of studies have examined the rela-
tionship of each individual biochemical marker to differ-
ent types and severity of periodontal diseases, there is still
no study comparing the efficiency of different markers in
evaluating disease severity. The aims of this study were,
therefore, to investigate the levels of CS, as determined by
our patented monoclonal antibody, raised against the
WF6 catabolic epitope of CS [30], and of ALP in GCF ob-
tained from patients with various disease statuses in com-
parison to healthy controls, and to compare the efficiency




Forty-three patients, including 10 patients with gingivitis
(5 males and 5 females) and 33 patients with chronic
periodontitis (16 males and 17 females), were recruited
from the Periodontology clinic, Faculty of Dentistry,
Chiang Mai University along with ten healthy volunteers
(5 males and 5 females). Written informed consent for
participation in this study was obtained from all partici-
pants. They were diagnosed according to the classifica-
tion of periodontal diseases by the American Academy of
Periodontology (AAP) 1999 [31]. The periodontal tissues
of healthy controls did not exhibit any clinical signs of
inflammation or destruction, whereas those of patientswith gingivitis showed clinical signs of gingival inflamma-
tion and bleeding upon probing without periodontal
pocket formation. The clinical features of patients with
chronic periodontitis comprised gingival inflammation
and bleeding and periodontal pocket formation from
alveolar bone loss as evaluated by the radiography. Pa-
tients and volunteers with underlying systemic diseases
were excluded from this study according to their medical
history obtained from an interview with dental practi-
tioners at the Oral Diagnostic Clinic, Faculty of Dentistry,
Chiang Mai University. The participants recruited in this
study were non-smoking and non-pregnant persons
without periodontal treatment or a history of antibiotic
or NSAID uses within three months prior to GCF sam-
pling. The proposal was approved by the Human Experi-
mentation Committee, Faculty of Dentistry, Chiang Mai
University.
Site selection
Five healthy sites from each healthy volunteer were se-
lected as the healthy group (H), while five gingivitis sites
from each patient with gingivitis were chosen as the gin-
givitis group (G). For patients with chronic periodontitis
a total of 200 sites were randomly selected and divided
into four groups according to a clinical attachment loss
(CAL). Fifty sites with clinical signs of gingival inflam-
mation and bleeding on probing without attachment loss
were identified as gingivitis sites in the periodontitis
group (PG), 50 sites with CAL 1–2 mm were identified
as slight periodontitis group (PSL), 50 sites with CAL
3–4 mm were identified as moderate periodontitis group
(PM), and 50 sites with CAL > 4 mm were identified as
severe periodontitis group (PSE).
Periodontal parameters
Clinical parameters, including probing depth (PD), gin-
gival recession, CAL, plaque index (PI) [32] and gingival
index (GI) [33] were recorded. The gingival recession
and PD were measured using a PCP-UNC15 probe (Hu-
Friedy, Chicago, IL, USA) from a reference point, the
cementum-enamel junction, and both data were then
combined and reported as CAL. All parameters were ex-
amined by one experienced periodontist (S.K.). The
intra-examiner calibration was performed with 98% and
96% agreement for PD and CAL, respectively.
GCF sample collection
One week before GCF collection, all clinical parameters
were recorded to avoid blood contamination during GCF
sampling. The GCF collecting technique was performed
as described previously [14]. The selected site was iso-
lated with cotton rolls and gently air dried with a triple
syringe. Periopaper strips (ProFlow™, Amityville, NY,
USA) and an analytical instrument (Periotron 8000™,
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and measure the GCF volumes ranging from 0.04 to
1.76 μl. All of the GCF samples were individually stored
at −80°C for further analyses. To recover biomolecules
from Periopaper strips, a 100-μl quantity of phosphate-
buffered saline was added and then agitated for 30 min at
room temperature. The GCF was recovered from the
Periopaper strips as previously described [14] with the re-
covery rate approximately 98%.
Competitive inhibition ELISA with WF6 monoclonal
antibody (mAb)
To determine CS (WF6 epitope) levels, a quantitative
ELISA method was performed using our WF6 mAb as
described previously [14]. Briefly, microtiter plates
(Maxisorp®, Nunc, Roskilde, Denmark) were coated
with 10 μg/ml shark PG-A1 fraction (100 μl/well) [34]
in coating buffer (20 mM sodium carbonate buffer,
pH 9.6) overnight at ambient temperature. The plates
were then washed three times with 150 μl/well of Tris-
incubation buffer (Tris-IB) [34] and dried. One hun-
dred and fifty μl per well of 1% (w/v) bovine serum
albumin (BSA) in Tris-IB was added to all plates and
then incubated at 37°C for 60 min. Thereafter, 100 μl/
well of the mixture, comprising 10 μl of GCF samples
or of standard competitors (Shark PG-AlDl fraction;
ranging from 39.06 to 10,000 ng/ml) in mAb against
the WF6 epitope of CS (patent number WO 2005/
118645 A1) at 1:100 dilution, were added in duplicate for
60 min at 37°C. Subsequently, the plates were washed,
and the IgM-specific peroxidase-conjugated anti-mouse
immunoglobulin (100 μl/well; 1:2,000) was added and in-
cubated at 37°C for 60 min. The plates were washed and
the peroxidase substrate (100 μl/well) was added at 37°C
for 20 min to allow the color to develop. The reactions
were stopped by addition of 50 μl/well of 4 M H2SO4.
The absorbance ratio at 492:690 nm was measured using
a Titertek Multiskan® MCC/340 multiplate reader (ICN/
Flow Laboratories, Costa Mesa, CA, USA). The minimal
detection level of ELISA for CS was 0.019 ng/ml. The CS
concentration in each sample was normalized by its GCF
volume, as measured by Periotron 8000™ [14].
Determination of ALP levels
The GCF samples were measured for ALP levels by
using an Alkaline Phosphatase Detection kit (Sigma-
Aldrich, St. Louis, MO, USA) according to the manu-
facturer’s instructions. Briefly, a 180 μl-quantity of
fluorometric assay buffer was added to the mixture
that contained 20 μl of GCF sample solution and 1 μl
of 10 mM substrate solution (4-methylumbelliferyl
phosphate disodium). Then, the mixtures were read at
360 nm for excitation wavelength and 440 nm for
emission wavelength in triplicate using a Fluorometer(Synergy H4 Hybrid Multi-Mode Microplate Reader,
Biotek®, Winooski, Vermont, USA). Known concentra-
tions of an ALP control (Sigma-Aldrich) were prepared
with the dilutions ranging from 0 to 1000 ng/ml. The con-
centrations of ALP in the GCF samples were measured
and calculated from a standard curve of these known con-
centrations. The ALP concentration in each sample was
normalized by its GCF volume, as measured by Periotron
8000™ [14].
Statistical analysis
The average age of participants was compared be-
tween groups by the paired t-test. The differences in
clinical parameters between groups were analyzed by
One-way ANOVA followed by Tukey’s post hoc test.
The Kolmogorov-Smirnov test was used to determine
the distribution of CS and ALP levels. The differences in
the CS or the ALP levels among different severities of
periodontal diseases were determined by the Wilcoxon
signed-rank test, and the differences between the two
groups of severities were determined by the Mann–
Whitney U-test. The correlations between CS or ALP
levels and clinical parameters were determined by Spear-
man’s correlation coefficient. The results were consid-
ered statistically significant when p-values were less than
0.05. Data were analyzed by using the Statistical Package
for Social Sciences version 17.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Demographic data and periodontal parameters
Mean ages of healthy controls, patients with gingivitis,
and patients with chronic periodontitis, were 27.80 ±
5.18, 26.5 ± 4.79 and 50.27 ± 9.67 years, respectively.
No significant difference between the mean age of
healthy controls and that of patients with gingivitis
was found, whereas the mean age of patients with
chronic periodontitis was significantly higher than that
of the healthy controls and of the gingivitis group
(p < 0.001). All four clinical parameters are illustrated
in Table 1. With regard to clinical parameters of peri-
odontal destruction, there were no significant differ-
ences in mean PD and CAL values between the healthy
(H), gingivitis (G) and gingivitis sites in chronic peri-
odontitis (PG) groups (Table 1). However, in patients
with chronic periodontitis, mean PD and CAL values
in the slightly (PSL), moderately (PM), and severely
(PSE) destructive sites were progressively increased
and to a significantly greater degree than those of non-
destructive sites (p < 0.05) (Table 1). With respect to
clinical parameters of periodontal inflammation, it was
demonstrated that mean GI and PI scores of the PM
and PSE groups were significantly higher than those of
the other groups (p < 0.05) (Table 1).
Table 1 A summary of four periodontal parameters (average ± SD) within all studied groups
Periodontal
parameters
H (n = 50) G (n = 50) Chronic periodontitis
PG (n = 50) PSL (n = 50) PM (n = 50) PSE (n = 50)
PD (mm) 2.60 ± 0.50a 3.00b 2.66 ± 0.48ab 3.90 ± 0.36c 5.32 ± 0.47d 7.28 ± 1.23e
CAL (mm) 0.00a 0.00a 0.00a 1.88 ± 0.33b 3.86 ± 0.78c 7.90 ± 1.45d
GI 0.00a 1.00b 1.02 ± 0.14b 1.08 ± 0.27b 1.54 ± 0.54c 2.26 ± 0.60d
PI 0.66 ± 0.52ab 1.36 ± 1.08c 0.52 ± 0.61a 1.06 ± 0.59bc 1.78 ± 0.74d 2.42 ± 0.67e
Different letters from a to e in each row represent an order of the averages from the lowest to the highest values and indicate statistically significant differences
(p < 0.05) between the studied groups, [healthy sites (H); gingivitis sites (G); gingivitis sites in chronic periodontitis (PG); slight periodontitis sites (PSL); moderate
periodontitis sites (PM); and severe periodontitis sites (PSE)], within each of the four periodontal parameters, including probing depth (PD), clinical attachment
loss (CAL), gingival index (GI), and plaque index (PI).
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Since the data distributions of CS and ALP levels were
not normal, median values of these levels and non-
parametric statistical methods were used to determine
the differences among different degrees of disease sever-
ity. It was found that the median CS levels among the H
(28.35 ng/ml), G (40.70 ng/ml), PG (34.80 ng/ml), and
PSL groups (45.05 ng/ml) were not significantly differ-
ent, while those of the PM (168.30 ng/ml) and PSE
groups (330.15 ng/ml) were significantly higher than
those in the other four groups (p < 0.001) (Figure 1). Fur-
thermore, a significant difference in median CS levels be-
tween moderately and severely destructive sites (PM vs.
PSE) was found (p < 0.001) (Figure 1). With respect to ALP
levels, no significant differences between the H (19.10 ng/
ml), G (21 ng/ml), PG (17.40 ng/ml) and PSL groups
(19.10 ng/ml) were observed (Figure 2). In contrast to CS
levels, the median ALP levels between moderately andFigure 1 Raised chondroitin sulfate (CS) levels in gingival crevicular f
median levels of CS in ng/ml, while the x-axis represents various groups of
chronic periodontitis, PSL = slight chronic periodontitis sites, PM =modera
Small open circles and small asterisks are outliers and extremes, respectivelseverely destructive sites [PM (27.40 ng/ml) vs. the PSE
group (37.05 ng/ml)] were not significantly different, al-
though a significant difference was still observed between
non-destructive to slightly destructive sites and moderately
to severely destructive sites (p < 0.001) (Figure 2).
Strong correlations observed between CS levels and
periodontal parameters
Correlations between CS or ALP levels and four periodon-
tal parameters, including PD, CAL, GI and PI, were deter-
mined as shown in Figure 3. It was found that the CS
concentrations were significantly correlated with PD and
CAL values (r = 0.632 and 0.634, respectively, p < 0.001)
(Figure 3A and B), whereas the ALP levels were weakly
correlated with these values (r = 0.287 and 0.282, p < 0.001)
(Figure 3E and F), indicating that the CS levels were associ-
ated with the degrees of periodontal tissue destruction
more than were the ALP levels. Moreover, the CS concen-
trations were significantly correlated with GI and PI scoresluid of patients with chronic periodontitis. The y-axis represents the
periodontal statuses. H = healthy, G = gingivitis, PG = gingivitis sites in
te chronic periodontitis sites, PSE = severe chronic periodontitis sites.
y. ***p < 0.001.
Figure 2 Elevated alkaline phosphatase (ALP) levels in gingival crevicular fluid of patients with chronic periodontitis. The y-axis
represents the median levels of ALP in ng/ml, whereas the x-axis represents various groups of periodontal statuses. H = healthy, G = gingivitis,
PG = gingivitis sites in chronic periodontitis, PSL = slight chronic periodontitis sites, PM =moderate chronic periodontitis sites, PSE = severe
chronic periodontitis sites. Small open circles and small asterisks are outliers and extremes, respectively. ***p < 0.001.
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D), whereas the ALP levels were slightly correlated with
these values (r = 0.242 and 0.313, p < 0.001) (Figure 3G and
H), reflecting that the correlation between the CS levels
and the degrees of periodontal tissue inflammation is
stronger than that between the ALP levels and the degrees
of inflammation. In sum, these findings suggest that raised
CS levels in GCF represent the degrees of periodontal tis-
sue destruction and inflammation better than do elevated
ALP levels.
Discussion
In this study, it was demonstrated that both CS and ALP
levels in GCF collected from patients with different peri-
odontal disease statuses were raised in accordance with
the severity of periodontal destruction. Low but detect-
able CS and ALP levels were observed in the H, G, PG
and PSL groups, whereas these levels were significantly
elevated in the PM and PSE groups when compared with
the non-destructive to slightly destructive periodontitis
groups. Interestingly, a significant difference in terms of
CS levels between moderate and severe chronic peri-
odontitis sites was demonstrated, whereas no significant
difference in ALP levels was found. Furthermore, the
levels of both biomolecules were significantly correlated
with all of four periodontal parameters, including the de-
grees of periodontal destruction (PD and CAL) and of
inflammation (GI and PI), but stronger correlations be-
tween all parameters and CS levels than between those
and ALP levels were evident. The reason we chose to
study the GCF levels of CS and ALP was because it waspreviously demonstrated that elevated levels of these two
biomolecules were closely associated with alveolar bone
destruction in chronic periodontitis [14,35], whereas
raised levels of other biomolecules, such as host-derived
pro-inflammatory mediators and proteolytic enzymes,
can reflect enhanced inflammation and destruction of
both soft and hard periodontal tissues. Therefore, we be-
lieve that among a number of biomolecules found within
GCF, CS and ALP are good candidates for this compara-
tive study to assess the different severities of alveolar
bone destruction in chronic periodontitis.
As anticipated, the average age of patients with chronic
periodontitis was more than those with gingivitis and
healthy controls due to the chronic nature of periodon-
titis, which is caused by dental plaque accumulation and
persistent inflammation of nearby periodontal tissues.
Nevertheless, the CS and ALP levels from the gingivitis
sites of patients with chronic periodontitis (PG) were not
significantly different from those of both patients with
gingivitis (G) and of healthy participants (H), although
the ages of patients and healthy volunteers in this study
were not matched. In contrast to the age difference be-
tween the chronic periodontitis and the remaining
groups, the gender distribution was not different among
groups to avoid bias in the study design. Furthermore, no
significant differences in clinical parameters between the
H, G and PG groups were found, whereas such parame-
ters in PSL, PM and PSE groups were enhanced accord-
ing to the severity of periodontitis.
In other previous reports, the studied cohorts were
mostly defined as healthy, gingivitis and chronic
Figure 3 Significant and positive correlations between the levels of either chondroitin sulfate (CS) or alkaline phosphatase (ALP) and
four clinical parameters. The CS levels in ng/ml (A, B, C, D) or the ALP levels in ng/ml (E, F, G, H) were associated with four periodontal
parameters, including probing depth (PD) in mm (A and E), loss of clinical attachment levels (CAL) in mm (B and F), gingival index (GI; C and G)
and plaque index (PI; D and H). Note stronger correlations were found between CS levels and all four clinical parameters than between ALP
levels and these parameters.
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periodontitis group was further divided into subgroups,
including PG, PSL, PM, and PSE, according to the disease
severity. We believe that detailed classification of chronic
periodontitis according to the severity of alveolar bone
destruction will better reflect the potential of biochemical
markers to distinguish different disease statuses that can
provide useful information and help clinicians in proper
treatment planning and periodontal maintenance, while
the conventional clinical parameters cannot [36,37].
In some previous studies, the association between ALP
and periodontal disease was reported, especially in active
diseased sites [16,35]. Significantly higher concentrations of
ALP were observed in periodontitis than in healthy and
gingivitis sites, and positive correlations of ALP levels with
clinical parameters, including PD and GI, were reported
[16,38]. These findings were similar to ours, and weak cor-
relations were also demonstrated both in those studies and
ours. With respect to CS levels, significantly higher levels
were shown in destructive sites than in non-destructive or
in slightly destructive sites, consistent with the findings
from our previous study [14]. Interestingly, even though
the ALP levels were higher in the destructive sites, no sig-
nificant difference in ALP levels was found between moder-
ate and severe destruction. On the other hand, a significant
difference in CS levels between moderate and severe de-
struction was observed, suggesting that the CS levels can
be better used than the ALP levels, to differentiate the clin-
ical severity of periodontitis, especially between moderate
and severe periodontal destruction, although the levels of
both biomolecules were elevated in the GCF of patients
with chronic periodontitis.
It was demonstrated in this study that either CS or ALP
levels were positively correlated with all four clinical pa-
rameters, which represent periodontal destruction and in-
flammation. The positive correlations of elevated CS and
ALP levels with increased clinical severity are in line with
the findings from previous studies [14,17,35]. However, in
this study, all four correlations between the clinical pa-
rameters and CS levels were stronger than those between
clinical parameters and ALP levels, corresponding with
the ability of CS levels, but not ALP levels, to differentiate
between moderate and severe periodontal destruction as
mentioned above. This may be because CS is derived only
from destruction of host extracellular matrix [39], whereas
ALP can be derived from both bacterial cells [40] and host
cells [41-43]. Moreover, it is recognized that raised CS
levels are principally due to alveolar bone resorption,
whereas elevated ALP levels are found to be implicated in
the process of bone formation [19] in addition to bone re-
sorption in destructive sites [35,44]. Lastly, CS is a repeat-
ing disaccharide unit of GAGs and should not be cleaved
by GCF proteinases, derived from both periodontal patho-
gens and host cells [45], whereas ALP enzyme can bedegraded by these proteinases during GCF storage. There
is still a limitation of this study due to its cross-sectional
design; thus, a further longitudinal study is required to
monitor any alterations in the GCF levels of these two
biomolecules during periodontal disease progression in
each individual tooth.
Conclusions
In summary, CS is a better biochemical marker to differ-
entiate moderate and severe alveolar bone destruction
and shows stronger correlations with all four clinical pa-
rameters than ALP. It is, therefore, suggested by all of
the findings from this study that CS is a better biochem-
ical marker for evaluating periodontal disease severity
than is ALP.
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